Research - Our May webinar covered ASCO primarily, as well as some other new and ongoing ideas in the healthcare sector. You’ll find the recording available for … Continue Reading
Premium: Read NowResearch - Revance Therapeutics (RVNC) reported topline data from their long-running cervical dystonia study with RT002 last night. Most importantly, all three cohorts (<200units, 200-300 units, and … Continue Reading
Premium: Read NowResearch - Sure enough, Sage’s (SAGE) phase 3 STATUS data have leaked into the third quarter. Our suggestion for some August hedge protection may still work, as … Continue Reading
Premium: Read NowResearch - Originally sent to PropThink members on May 3, 2017. Selecta Biosciences (SELB) has been weak since our suggestion two weeks ago, but we still like … Continue Reading
Premium: Read NowResearch - Many investors will be familiar with the failed commercial efforts at, and subsequent bankruptcy of, Savient Pharmaceuticals (SVNT). It was a spectacle almost a decade … Continue Reading
Premium: Read NowResearch - We’ve discussed Paratek Pharmaceuticals (PRTK) in a few recent webinars, and wanted to follow up in the wake of quality CABP data for omadacycline IV-to-Oral. … Continue Reading
Premium: Read NowResearch - Biotech stocks are rolling over a little, possibly due to the release of Senator Al Franken and Democrats’ proposed bill to curb drug prices in … Continue Reading
Read Now
